Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Ambroise Wu
Observed names:
A. Wu,
Wu, A.,
Wu, Ambroise
Institution:
Zymeworks (Canada)
Observed institutions:
Centre National de la Recherche Scientifique,
Inserm,
Aix-Marseille Université,
University of Wrocław,
Zymeworks (Canada),
Centre d’Immunologie de Marseille-Luminy
show all 6
ORCID:
0000-0001-8568-8331
Observed ORCID:
0000-0001-8568-8331
OpenAlex ID:
A5087203944
Works
39
Awards
1
Phosphoinositides regulate the TCR/CD3 complex membrane dynamics and activation
2018
·
Nassima Chouaki Benmansour
, Kilian Ruminski
, et al.
·
Scientific Reports
·
36
PDF
Do ABC transporters regulate plasma membrane organization?
2020
·
Ambroise Wu
, Karolina Wojtowicz
, et al.
·
Cellular & Molecular Biology Letters
·
33
PDF
Controlling T cells spreading, mechanics and activation by micropatterning
2021
·
Anaïs Sadoun
, Martine Biarnes-Pelicot
, et al.
·
Scientific Reports
·
25
PDF
ABCA1 transporter reduces amphotericin B cytotoxicity in mammalian cells
2019
·
A. Wu
, E. Grela
, et al.
·
Cellular and Molecular Life Sciences
·
17
PDF
ABCA1 transporter promotes the motility of human melanoma cells by modulating their plasma membrane organization
2023
·
Ambroise Wu
, Ewa Mazurkiewicz
, et al.
·
Biological Research
·
14
PDF
ABCA1 modifies plasma membrane organization of living cells
2025
·
Mateusz Kondratowicz
, Ambroise Wu
, et al.
·
Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
·
2
ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026
·
Samuel Lawn
, Andrea Hernandez Rojas
, et al.
·
Clinical Cancer Research
·
1
Systematic Evaluation of Maleimide Spacer Impact on Drug-Linker Deconjugation in Antibody-Drug Conjugates Ex Vivo and In Vivo
2026
·
Andrea Hernández Rojas
, Jodi Wong
, et al.
·
Bioconjugate Chemistry
·
1
Abstract 2874: ZW327, a novel Ly6E-targeting antibody-drug conjugate bearing a topoisomerase 1 inhibitor payload
2025
·
Dunja Urosev
, Saki Konomura
, et al.
·
Cancer Research
·
1
6 Oral: ZW220, a NaPi2b-directed topoisomerase I inhibitor Antibody-Drug Conjugate, demonstrates compelling preclinical activity in NSCLC, ovarian and uterine cancer models, with a favorable toxicology profile in non-human primates
2024
·
A. Hernandez
, D. Urosev
, et al.
·
European Journal of Cancer
·
1
177 (PB165): ZW251, a novel glypican-3-targeting antibody-drug conjugate bearing a topoisomerase I inhibitor payload demonstrates compelling preclinical activity in hepatocellular carcinoma models
2024
·
L. Madera
, A. Wu
, et al.
·
European Journal of Cancer
·
1
Abstract 1862: ZW191 - a FRα-targeting antibody drug conjugate with strong preclinical activity across multiple FRα-expressing indications
2024
·
Sam Lawn
, Andrea Hernandez Rojas
, et al.
·
Cancer Research
·
1
Author Correction: Phosphoinositides regulate the TCR/CD3 complex membrane dynamics and activation
2020
·
Nassima Chouaki Benmansour
, Kilian Ruminski
, et al.
·
Scientific Reports
·
1
PDF
Supplementary Figure S1 from ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026
·
Samuel Lawn
, Andrea Hernandez Rojas
, et al.
Supplementary Figure S3 from ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026
·
Samuel Lawn
, Andrea Hernandez Rojas
, et al.
Data from ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026
·
Samuel Lawn
, Andrea Hernandez Rojas
, et al.
Supplementary Figure S10 from ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026
·
Samuel Lawn
, Andrea Hernandez Rojas
, et al.
Supplementary Figure S2 from ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026
·
Samuel Lawn
, Andrea Hernandez Rojas
, et al.
Supplementary Figure S7 from ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026
·
Samuel Lawn
, Andrea Hernandez Rojas
, et al.
Supplementary Figure S12 from ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026
·
Samuel Lawn
, Andrea Hernandez Rojas
, et al.
Supplementary Figure S9 from ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026
·
Samuel Lawn
, Andrea Hernandez Rojas
, et al.
Supplementary Table T3 from ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026
·
Samuel Lawn
, Andrea Hernandez Rojas
, et al.
Supplementary Figure S6 from ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026
·
Samuel Lawn
, Andrea Hernandez Rojas
, et al.
Supplementary Figure S13 from ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026
·
Samuel Lawn
, Andrea Hernandez Rojas
, et al.
Supplementary Figure S4 from ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026
·
Samuel Lawn
, Andrea Hernandez Rojas
, et al.
Show more works
View as search
Works count:
39
Citation count:
134
H-index:
5
I10-index:
5
Year
Topic
Type
